Total Funding
16
38
Total FundingSeries C raised
Growth Score 16 in past quarter
-17 pts
Heat Score 38 in past quarter
-14 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
75218
Visterra researches on and develops therapeutic and diagnostic products for the treatment of infectious diseases.
Brian Pereira: President & CEO & Board MemberPast Role: AMAG Pharmaceuticals, President & CEO- Peter Courossi: Chief Financial OfficerPast Role: Transform Pharmaceuticals, CFO
About the Company
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and
changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

